Surrozen shares are trading higher after the company announced it earned a $10 million payment as part of a collaboration with Boehringer that is advancing the development of SZN-413 for retinal vascular diseases.
Portfolio Pulse from Benzinga Newsdesk
Surrozen shares rise following a $10 million payment from Boehringer for the development of SZN-413, a treatment for retinal vascular diseases.
September 24, 2024 | 6:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surrozen's stock is trading higher due to a $10 million payment from Boehringer, which is part of their collaboration on SZN-413 for retinal vascular diseases.
The $10 million payment signifies progress in Surrozen's collaboration with Boehringer, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100